Physician profile
Daniel H Morgan
NPI 1023360930
$3,083.63
in general payments reported to CMS, 2019-2025
18 companies · $749 in 2025
The $749 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.66 · 2022: $296 · 2023: $999 · 2024: $1,027 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,750 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,750.30 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $562.63 | 2023-2025 | |
| Glaxosmithkline, LLC. | $430.56 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Currax Pharmaceuticals LLC | $405.08 | 2023-2025 | Contrave, Nexletol, Nexlizet |
| Amgen INC. | $348.57 | 2023-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $319.02 | 2023-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $285.10 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.62 | 2023-2025 | Jardiance |
| Heartflow, INC. | $120.29 | 2024 | |
| Novo Nordisk INC | $99.04 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Sumitomo Pharma America, INC. | $69.74 | 2025 | Gemtesa |
| Dexcom, INC. | $40.01 | 2023-2025 | Dexcom G6 Transmitter |
| Baxter Healthcare | $31.98 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $29.35 | 2025 | Eliquis |
| Organon LLC | $28.54 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.57 | 2024 | Crysvita |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $18.84 | 2022 | |
| Lundbeck LLC | $17.01 | 2024 | Rexulti |
| Si-Bone, INC. | $13.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.